PRODROME results published in The Lancet Stigmatising attitudes about migraine still persist ADVANCE analysis shows favourable benefit:risk analysis for atogepant CHALLENGE-MIG: Galcanezumab and rimegepant equally effective for migraine prevention Galcanezumab improves central sensitisation in patients with migraine Real world high responder rates for atogepant and rimegepant UNITE data show fremanezumab benefits on disability scores Migraine reduction with bariatric surgery linked to CGRP change

Partnership & Outreach

Through its unique global network of researchers and clinicians, the CGRP Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of the burden, disability and cost associated with migraine.

Educational Partners and Supporters

Lilly

This program is funded in part via an independent educational grant from AbbVie

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2023 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |